Navigation Links
Intrinsic Enrolls First Patient in Barricaid® Trial
Date:2/17/2011

WOBURN, Mass., Feb. 17, 2011 /PRNewswire/ -- Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid® device. Barricaid is designed to prevent reherniations following lumbar discectomy, while allowing the surgeon to retain as much of the native nucleus as possible preserving normal disc height and biomechanics. Barricaid accomplishes this by providing the added security of a bone-anchored device that can be used to close larger anular defects or in cases where anular integrity is in question.

The procedure was performed by Guido Dua, M.D., Chief of Neurosurgery, Middelheim Hospital in Antwerp, Belgium. Robert Hes, MD, Principal Investigator at Middelheim, stated, "What I like about the Barricaid device is that it provides an elegant solution to possible reherniation. Barricaid allows for a limited discectomy while offering the potential for secure closure of the anular defect and a reduction in both the risk of recurrent disc herniation and disc height loss.  I was very satisfied with the simplicity and ease of the procedure. I anticipate that we will be able to recreate the outstanding results seen in prior Barricaid studies."

"We are pleased to have begun our randomized study in Europe," said Noel Rolon, Intrinsic Vice President, Regulatory and Clinical Affairs. "The fact that we have started enrolling patients so quickly indicates the level of enthusiasm among our investigators.  It is clear that the positive clinical and commercial results recently presented at the DWG meeting in Bremen and published in the November 2010 issue of the European Spine Journal, provide a strong foundation for this post-marketing study."

Intrinsic is enrolling up to 800 patients in a prospective, randomized, superiority study comparing Barricaid to traditional limited discectomy. "We are exc
'/>"/>

SOURCE Intrinsic Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction
2. Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
3. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
4. Cardiogenesis Enrolls First Two Patients in Its Feasibility Study of the PHOENIX® Combination Delivery System
5. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
6. BHR Pharma Enrolls First Patient in Phase 3 SyNAPSe Traumatic Brain Injury Trial
7. Crux Biomedical Enrolls First Patient in Its Retrieve 2 U.S. Pivotal Trial
8. Ophthotech Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration
9. PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA
10. Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
11. Facet Solutions Enrolls 100th Patient in US Pivotal IDE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015  Boston Children,s ... benefiting from 3D printing of their anatomy before ... life-threatening cerebrovascular malformations (abnormalities in the brain,s blood ... Reporting online today in the Journal of ... of 3D printing and synthetic resins to create ...
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
(Date:7/31/2015)... 31, 2015 According to a ... Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold ... Global Analysis & Forecast to 2019", published by MarketsandMarkets, ... $911.1 Million 2014 and is estimated to grow to ... 9.4% from 2014 to 2019. Browse ...
Breaking Medicine Technology:3D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
... tirofiban also edges abciximab, CHICAGO, March ... randomized,study is answering important questions about the ... patients with a type of heart,attack known ... drug-eluting stents outperformed bare-metal stents, and high-dose,tirofiban, ...
... and type, prasugrel bests clopidogrel, CHICAGO, March ... activity in patients with acute coronary syndromes (ACS) ... than half the risk of,thrombosis, or blood clotting, ... data from the Trial to Assess Improvement in ...
Cached Medicine Technology:Drug-Eluting Stents Outperform Bare Stents in Heart Attack 2Drug-Eluting Stents Outperform Bare Stents in Heart Attack 3Drug-Eluting Stents Outperform Bare Stents in Heart Attack 4TRITON-TIMI 38 Stent Analysis Favors Prasugrel 2TRITON-TIMI 38 Stent Analysis Favors Prasugrel 3
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic Georgia and Peach State ... Girl Scout "Be a Friend First" program. Representatives from Peach State Health Plan presented ... State Health Plan and our parent company, Centene Corporation, are dedicated to raising anti-bullying ...
(Date:7/31/2015)... IL (PRWEB) , ... July 31, 2015 , ... The ... Boston, when Major League Baseball and the Boston Red Sox honor Ice Bucket co-founders ... the challenge. MLB is donating $100,000 to further collaborative efforts among the ALS organizations ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... for the Northern District of Ohio, Western Division (Case No. 3:15-cv-00397) involving the ... 3:15-cv-00397), the women experienced spontaneous migration of their Implanon® implants, inability to locate ...
(Date:7/31/2015)... ... ... The alarm was ringing. Hugh Chatfield, survivor of a severe 1987 brain injury, almost slept ... equipment was set up to depict the newly poured concrete. With a clear view of ... speaks for itself. Chatfield is also a highly praised safety and drug education speaker/comedian. , ...
(Date:7/31/2015)... ... 2015 , ... Patients with higher levels of a key protein are at ... Communications and led by researchers from the Icahn School of Medicine at Mount Sinai. ... led to greater production of the related RNT1 protein, which caused kidney cells to ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3
... broke his silence for the first time. Since his parents broke ... problem of substance abuse. ,He revealed that he was ... He was being treated for a number of illnesses as a ... the name of the drug that he had been using. ...
... today issued the "Critical Path Opportunities for Generic Drugs" ... impede the development of generic versions of commonly used ... Critical Path Initiative, established in 2004 to discern what ... device along the critical path from discovery, or proof ...
... but a Dartmouth discovery that a cousin of niacin prolongs ... ,The research, reported in the May 4 issue ... yeast cells, much like calorie restriction does in animals. It ... ,Radical calorie reduction can extend life. Dieting or ...
... women who took an epilepsy drug during their pregnancy are ... In question is the drug valproate (already at the ... has damaged children). Valproate seems to double the chance that ... ,Around 140 British families claim that their children are ...
... research published in the journal Proceedings of the National ... produce// an antibiotic which inhibits the work of an ... from attack. ,Although such so-called gene-for-gene interactions ... examples of a single gene in a pathogen targeting ...
... an agency of the New York state government has lashed ... Hospital// as a shameful "chamber of filth, decay, indifference and ... Union, the agency has filed a suit in the federal ... where patients are subjected to overcrowded conditions, physical abuse and ...
Cached Medicine News:Health News:Cousins Recovering from His Substance Abuse Problem 2Health News:New Critical Path Report Highlights Research Needed to Foster Generic Drug Development 2Health News:Vitamin Extends Life in Yeast, Dartmouth Medical School Researchers Find 2Health News:Vitamin Extends Life in Yeast, Dartmouth Medical School Researchers Find 3Health News:Anti-Epileptic Drug Intake May Result In Children With Mental Retardation 2Health News:Scientists Discover Rare ‘gene-for-gene’ Interaction That Helps Bacteria Kill Their Ho 2Health News:Suit Filed Against Horrors of Psychiatric Ward in New York Hospital 2
Freer elevator, double end, 7 1/4", S/B....
... The Surgifoam* absorbable gelatin sponge, U.S.P. ... gelatin absorbable sponge intended for hemostatic ... surface. The sponge is off-white and ... speed to hemostasis, highly favorable surgeon ...
... absorbable gelatin sponge, U.S.P. is a ... sponge intended for hemostatic use by ... sponge is off-white and porous in ... hemostasis, highly favorable surgeon preference ratings ...
16 mm diameter curved probes with suture eyes just back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
Medicine Products: